**Supplemental Table 5**. Treatment-Emergent Extrapyramidal Symptoms Determined by Rating Scale Scores in the All-Treated Set.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Scale | PBO | ASN 2.5 mg bid | ASN 5 mg bid | OLZ 15 mg qd |
| AIMS severity abnormal movements (item 8) score ≥2  na  n (%) | 101 2 (2.0) | 97 1 (1.0) | 113  0 (0.0) | 45 0 (0.0) |
| BARS global score ≥2  na  n (%) | 98 3 (3.1) | 94 1 (1.1) | 113 3 (2.7) | 42 1 (2.4) |
| SARS mean total score >3  na  n (%) | 90 3 (3.3) | 87 2 (2.3) | 107 3 (2.8) | 42 3 (7.1) |
| AIMS, Abnormal Involuntary Movement Scale; ASN, asenapine; BARS, Barnes Akathisia Rating Scale; bid, twice daily; OLZ, olanzapine; PBO, placebo; qd, once daily; SARS, Simpson-Angus Rating Scale. Treatment-emergent extrapyramidal symptom by rating scale scores are measured after baseline and up to 7 days after study medication stop date.  aRestricted to patients who had the following at baseline: an AIMS severity of abnormal movements (item 8) score <2, a BARS global score <2, or a SARS total score ≤3, respectively. | | | | |